Novo Nordisk Owner Will Invest Ozempic Profits in Deals in Asia
- Speaking at Davos, Novo Holdings CEO sees uncertainty in 2024
- Company manages more than $100 billion of investments
Ozempic injection pens.
Photographer: Carsten Snejbjerg/BloombergThis article is for subscribers only.
The main owner of Novo Nordisk A/S is planning more acquisitions, including investments in Asia, using dividends it receives from the drugmaker’s blockbuster medicines for obesity and diabetes.
Novo Holdings, which controls 77% of the votes in what is now Europe’s most valuable company, will “absolutely” be active in dealmaking, Chief Executive Officer Kasim Kutay said in an interview with Bloomberg TV’s Francine Lacqua from Davos. “We need to scale up and put that money to good work.”